High Content Screening Market
This report studies the global high content screening market over the forecast period of 2013 to 2018. The global high content screening market was valued at an estimated $362.2 million in 2013 and is expected to reach $615.8 million by 2018, growing at a CAGR of 11.2% from 2013 to 2018.
Enhanced accuracy of cell imaging and analysis systems helps in reducing the drug discovery time period and costs, which is a major factor driving the growth of this market. Furthermore, the increasing use of HCS in toxicity studies in the early phase of drug discovery is another factor that propels the growth of this market. Government support for the growth of innovative technologies and rising demand for outsourcing of drug discovery services, especially in the Asian region, are also major reasons for the high growth of this market. Based on HCS products, the instruments market commanded the largest share of 43% in 2013. However, the HCS software market is poised to grow at the highest CAGR from 2013 to 2018.
Based on geography, the global high content screening market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America accounted for the largest share of the market in 2013. This large share of the North American region can be attributed to the various collaborations among prominent players for developing and marketing new products in the market.
The major players in the high content screening market include Thermo Fisher Scientific (U.S.), Molecular Devices (acquired by Danaher Corporation) (U.S.), PerkinElmer, Inc. (U.S.), GE Healthcare (U.K.), Becton, Dickinson and Company (U.S.), Cell Signaling Technology (U.S.), Genedata AG (Switzerland), Merck KGaA (Germany), Thorlabs, Inc. (U.S.), and Yokogawa Electric Corporation (Japan), among
Enhanced accuracy of cell imaging and analysis systems helps in reducing the drug discovery time period and costs, which is a major factor driving the growth of this market. Furthermore, the increasing use of HCS in toxicity studies in the early phase of drug discovery is another factor that propels the growth of this market. Government support for the growth of innovative technologies and rising demand for outsourcing of drug discovery services, especially in the Asian region, are also major reasons for the high growth of this market. Based on HCS products, the instruments market commanded the largest share of 43% in 2013. However, the HCS software market is poised to grow at the highest CAGR from 2013 to 2018.
Based on geography, the global high content screening market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America accounted for the largest share of the market in 2013. This large share of the North American region can be attributed to the various collaborations among prominent players for developing and marketing new products in the market.
The major players in the high content screening market include Thermo Fisher Scientific (U.S.), Molecular Devices (acquired by Danaher Corporation) (U.S.), PerkinElmer, Inc. (U.S.), GE Healthcare (U.K.), Becton, Dickinson and Company (U.S.), Cell Signaling Technology (U.S.), Genedata AG (Switzerland), Merck KGaA (Germany), Thorlabs, Inc. (U.S.), and Yokogawa Electric Corporation (Japan), among